BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30688730)

  • 1. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
    Nobashi T; Baratto L; Reddy SA; Srinivas S; Toriihara A; Hatami N; Yohannan TK; Mittra E
    Clin Nucl Med; 2019 Apr; 44(4):e272-e279. PubMed ID: 30688730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 3.
    Eshghi N; Garland LL; Nia E; Betancourt R; Krupinski E; Kuo PH
    J Nucl Med Technol; 2018 Sep; 46(3):260-264. PubMed ID: 29599403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
    Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
    Wachsmann JW; Ganti R; Peng F
    Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy.
    Jin P; Li J; Meng Y; Wu L; Bai M; Yu J; Meng X
    Cancer Lett; 2021 Nov; 520():91-99. PubMed ID: 34237407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
    Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
    J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic impact of
    Tatar G; Alçin G; Sengul Samanci N; Erol Fenercioglu Ö; Beyhan E; Cermik TF
    Clin Transl Oncol; 2022 Oct; 24(10):1903-1913. PubMed ID: 35594002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment response evaluation with
    Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in Advanced NSCLC: [
    Ferrari C; Santo G; Merenda N; Branca A; Mammucci P; Pizzutilo P; Gadaleta CD; Rubini G
    Diagnostics (Basel); 2021 Sep; 11(9):. PubMed ID: 34574022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Utility of
    Chen H; Jin R; Wang Y; Li L; Li K; He Y
    Biomed Res Int; 2018; 2018():1823710. PubMed ID: 29686996
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
    J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does dual-time-point
    Wu B; Zhao Y; Zhang Y; Tan H; Shi H
    Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma to treatment.
    Fujii H; Tanaka H; Nomoto Y; Harata N; Oota S; Isogai J; Yoshida K
    Medicine (Baltimore); 2018 Apr; 97(17):e0543. PubMed ID: 29703034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute number of new lesions on
    Anwar H; Sachpekidis C; Winkler J; Kopp-Schneider A; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):376-383. PubMed ID: 29124281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer.
    Chen R; Zhou X; Liu J; Huang G
    J Nucl Med; 2016 Jul; 57(7):1040-4. PubMed ID: 26966162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.